

## **Aiforia has received a funding decision from Business Finland to accelerate the development of AI-assisted software solutions for clinical pathology and drug development**

Aiforia Technologies Plc, Company release, 27 April 2023 at 12:00 a.m. EEST

Aiforia has received a funding decision from Business Finland to accelerate the development of AI-assisted software solutions for clinical pathology and drug development. The estimated cost for the project is EUR 14,6 million for two years, of which Business Finland will fund a maximum of 50% (EUR 7,3 million) in the form of a loan.

"The growing global market will need the expertise, advanced technologies, and digital solutions of Finnish companies and research organizations. Aiforia is a pioneer in its field with its AI-powered software solutions and has signed significant international collaboration and customer agreements. Business Finland's funding can accelerate the company's growth into an international success story, and Aiforia is already growing well globally," says Susanna Kaitera, Senior Advisor, Health and Wellbeing, Business Finland.

This product development project aims to promote the scaling of the business and accelerate growth by expanding features of existing software solutions and creating entirely new ones. The project includes developing deep learning-based artificial intelligence models and software solutions for clinical pathology and pre-clinical research.

"We're excited about this positive funding decision. With the funding, we can accelerate the development of software solutions for clinical diagnostics and pre-clinical drug development", says Jukka Tapaninen, CEO of Aiforia Technologies Plc. "AI-assisted diagnostics in pathology and pre-clinical research is growing rapidly. Recognizing the challenges of traditional methods, customers are now looking for new solutions to enhance the analysis of medical images. With the help of this funding, we can bring new products to market faster and secure our position in an increasingly competitive space."

## **Further inquiries**

Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc, tel. +358405009878

<https://investors.aiforia.com/>

## **Certified Adviser**

UB Securities Ltd, tel. +358 9 25 380 225

## **About Aiforia**

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep-learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud-based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more. Find out more at [www.aiforia.com](http://www.aiforia.com)